Acute effect of the renally excreted low-calorie sweetener, acesulfame potassium (Ace-K), on urinary glucose excretion in people with type 2 diabetes. - Trial ANZCTR12623000094673
Access comprehensive clinical trial information for ANZCTR12623000094673 through Pure Global AI's free database. This Not Applicable trial is sponsored by The University of Adelaide and is currently Not yet recruiting. The study focuses on Type 2 diabetes.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Australian New Zealand Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The University of Adelaide
The Hospital Research Foundation;; The Hospital Research Foundation
Timeline & Enrollment
Not Applicable
Feb 01, 2023
Mar 01, 2024
Primary Outcome
The difference in accumulated urinary glucose excretion (= urine glucose concentrations * urine volume) between Ace-K, sucralose and placebo days.
Summary
Low-calorie sweeteners (LCS) have been widely used in food and beverages in recent decades. However, a recent World Health Organisation (WHO) report highlighted that people who consume LCS regularly have an increased risk of developing type 2 diabetes (T2D). Acesulfame potassium (Ace-K) is a widely used low-calorie sweetener that is absorbed from the gut and excreted in the urine. We want to find out whether Ace-K consumption, as compared with water and a poorly absorbed LCS, sucralose, reduces the amount of glucose excreted in the urine in people with T2D, which would promote higher blood glucose levels.
ICD-10 Classifications
Data Source
Australian New Zealand Clinical Trials Registry
ANZCTR12623000094673
Non-Device Trial